Do parameters of cardiac function predict long-term outcomes in patients with pulmonary arterial hypertension? Data from SERAPHIN, a randomized controlled study of macitentan

CHEST Journal ◽  
2013 ◽  
Vol 144 (4) ◽  
pp. 870B
Author(s):  
Richard Channick ◽  
Marion Delcroix ◽  
Nazzareno Galiè ◽  
Hossein A. Ghofrani ◽  
Pavel Jansa ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Cardiac Function ◽  
Arterial Hypertension ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Long Term Outcomes ◽  
Randomized Controlled ◽  
Pulmonary Arterial

Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol

2009 ◽  
Vol 36 (10) ◽  
pp. 2244-2249 ◽  
Author(s):  
DAVID B. BADESCH ◽  
MICHAEL D. McGOON ◽  
ROBIN J. BARST ◽  
VICTOR F. TAPSON ◽  
LEWIS J. RUBIN ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Survival Rates ◽  
Randomized Controlled Study ◽  
Extension Study ◽  
Controlled Study ◽  
Open Label ◽  
Randomized Controlled ◽  
Pulmonary Arterial ◽  
Longterm Survival

Objective.Pulmonary arterial hypertension (PAH) remains challenging to treat, especially in association with scleroderma. We examined survival rates among patients with PAH in association with scleroderma who received epoprostenol (Flolan®) through continuous intravenous (IV) infusion in an uncontrolled open-label 3-year extension study following an initial randomized, controlled 12-week study.Methods.One hundred two patients diagnosed with PAH in association with scleroderma who received epoprostenol were included in the analyses. This included 51 PAH patients from a subject population of 56 who received epoprostenol in the randomized controlled study, and 46 patients from an initial population of 55 subjects on conventional therapy in the randomized controlled study, who received epoprostenol in the extension study. All patients in this extension study received open-label epoprostenol. Adverse events, survival, and dosing information were collected throughout the study.Results.The probabilities of survival during the first and second years for all subjects who received epoprostenol during the initial randomized controlled study or during the extension study were 0.71 and 0.52, respectively. This measure remained constant at 0.48 during the third and fourth years.Conclusion.This study reports longterm survival rates for patients with scleroderma-associated PAH treated with IV epoprostenol. Although comparisons to historical data should be made with caution, this study reports a better survival outcome than natural history data on patients with scleroderma-associated PAH.

scholarly journals Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol

2017 ◽  
Vol 8 (1) ◽  
pp. 204589321774805 ◽  
Author(s):  
Barbara L. LeVarge ◽  
Anica C. Law ◽  
Blanche Murphy
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Adverse Events ◽  
Arterial Hypertension ◽  
Long Term Outcomes ◽  
Pulmonary Arterial

Infection, thrombosis, and catheter dislodgment are well-recognized potential complications of chronic intravenous prostanoid therapy for pulmonary arterial hypertension. As long-term outcomes of pulmonary hypertension patients improve, novel adverse events are likely to arise. We describe the sudden development of unexplained hypotension and lightheadedness in a patient receiving intravenous epoprostenol for several years, ultimately determined to be due to an unusual catheter complication, not previously described in this population.

Sign in / Sign up

Export Citation Format

Share Document